L Cortesi
Overview
Explore the profile of L Cortesi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
374
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Agostinetto E, Bruzzone M, Hamy A, Kim H, Chiodi C, Bernstein-Molho R, et al.
ESMO Open
. 2024 Sep;
9(10):103714.
PMID: 39288653
Background: Young women with breast cancer (BC) have an increased chance of carrying germline BRCA pathogenic variants (PVs). Limited data exist on the prognostic impact of tumor histology (i.e. ductal...
2.
Incorvaia L, Badalamenti G, Novo G, Gori S, Cortesi L, Brando C, et al.
ESMO Open
. 2023 Dec;
9(1):102196.
PMID: 38118367
Background: The BRCA proteins play a key role in the homologous recombination (HR) pathway. Beyond BRCA1/2, other genes are involved in the HR repair (HRR). Due to the prominent role...
3.
Cortesi L, Venturelli M, Cortesi G, Caggia F, Toss A, Barbieri E, et al.
ESMO Open
. 2023 Apr;
8(2):101207.
PMID: 37028000
Background: BRCA1/2-related metastatic breast cancers (mBC) are sensitive to DNA-damage agents and show high tumor-infiltrated lymphocytes. We hypothesized that the association between pembrolizumab and carboplatin could be active in BRCA-related...
4.
Viansone A, Pellegrino B, Omarini C, Pistelli M, Boggiani D, Sikokis A, et al.
Breast
. 2022 Aug;
65:145-150.
PMID: 35970028
Background: HER2-positive breast cancers are rare amongst BRCA mutation carriers. No data exist regarding clinicopathological characteristics and prognosis of this subgroup of patients. Materials And Methods: Using a retrospective matched...
5.
Russo A, Incorvaia L, Capoluongo E, Tagliaferri P, Gori S, Cortesi L, et al.
ESMO Open
. 2022 May;
7(3):100459.
PMID: 35597177
Constitutional BRCA1/BRCA2 pathogenic or likely pathogenic variants (PVs) are associated with an increased risk for developing breast and ovarian cancers. Current evidence indicates that BRCA1/2 PVs are also associated with...
6.
Toss A, Isca C, Venturelli M, Nasso C, Ficarra G, Bellelli V, et al.
ESMO Open
. 2021 Feb;
6(2):100055.
PMID: 33582382
Introduction: The present analysis aims to evaluate the consequences of a 2-month interruption of mammographic screening on breast cancer (BC) stage at diagnosis and upfront treatments in a region of...
7.
Pasina L, Novella A, Cortesi L, Nobili A, Tettamanti M, Ianes A
Eur J Clin Pharmacol
. 2020 Apr;
76(7):1011-1019.
PMID: 32314001
Purpose: Pharmacoepidemiological studies aimed to distinguish drug use in nursing home (NH) residents with and without dementia could be useful to target specific interventions to improve prescribing. This multicenter retrospective...
8.
Implementation of the Frailty Index in hospitalized older patients: Results from the REPOSI register
Cesari M, Franchi C, Cortesi L, Nobili A, Ardoino I, Mannucci P
Eur J Intern Med
. 2018 Jun;
56:11-18.
PMID: 29907381
Background: Frailty is a state of increased vulnerability to stressors, associated to poor health outcomes. The aim of this study was to design and introduce a Frailty Index (FI; according...
9.
Cazzaniga M, Cortesi L, Ferzi A, Scaltriti L, Cicchiello F, Ciccarese M, et al.
Int J Breast Cancer
. 2018 Jan;
2017:1683060.
PMID: 29333297
Triple-negative breast cancer (TNBC) shows a very bad prognosis, even in early stages of disease. Metronomic chemotherapy refers to the minimum biologically effective dose of a chemotherapy agent given as...
10.
Musolino A, Falcini F, Sikokis A, Boggiani D, Rimanti A, Pellegrino B, et al.
Eur J Cancer
. 2017 Nov;
88:10-20.
PMID: 29175735
Background: Although human epidermal growth factor receptor 2 (HER2) overexpression is associated with poor prognosis, patients (pts) with pT1a N0M0 breast cancers (BCs) have an excellent outcome across all subtypes....